What one share of Xeris Biopharma Holdings holds
Xeris Biopharma Holdings, Inc. along with its subsidiaries, is referenced herein as the "Company", "Xeris", "Xeris Biopharma", "we" or "our". Throughout this document, unless otherwise noted, references to Gvoke include Gvoke PFS, Gvoke HypoPen, and Gvoke Kit.
Xeris Biopharma Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.86 |
|---|---|
| Profit | −$0.10 |
| Cash and investments | $0.70 |
| Debt | $1.46 |
| Book value | −$0.06 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.48 | −$2.14 | $0.01 | −$1.90 | — | $0.57 |
| 2021 | $0.63 | −$1.55 | $0.01 | −$1.22 | — | $0.76 |
| 2022 | $0.81 | −$0.70 | — | — | — | $0.33 |
| 2023 | $1.19 | −$0.45 | — | — | — | −$0.05 |
| 2024 | $1.38 | −$0.37 | — | — | — | −$0.20 |
| 2025 | $1.69 | $0.00 | — | — | — | $0.08 |
Common questions about Xeris Biopharma Holdings
How much does one share of Xeris Biopharma Holdings earn?
Over the last 12 months, Xeris Biopharma Holdings lost $0.10 for each share on $1.86 of sales.
Does Xeris Biopharma Holdings pay a dividend?
Xeris Biopharma Holdings didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Xeris Biopharma Holdings’s book value per share?
Xeris Biopharma Holdings’s book value is negative (−$0.06 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Xeris Biopharma Holdings have?
Each share of Xeris Biopharma Holdings has $0.70 of cash and investments and $1.46 of debt, as of June 30, 2026.
Has Xeris Biopharma Holdings bought back shares?
Xeris Biopharma Holdings’s share count rose about 305% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.